GLP-1 Weight Loss Programs: The Complete Guide

GLP-1 (glucagon-like peptide-1) receptor agonists are a class of medications originally developed for type 2 diabetes that have shown significant results for weight loss. They work by mimicking a natural hormone that regulates appetite and blood sugar. Common medications in this space include semaglutide (Ozempic, Wegovy); tirzepatide (Mounjaro, Zepbound) is a closely related dual GIP/GLP-1 receptor agonist.

Monthly costs range from roughly $149 to $599+ depending on the provider, medication type (compounded vs. brand-name), and dosage. Compounded semaglutide programs typically start around $149–$299/month, while brand-name medications like Wegovy or Zepbound can cost $500+ even through telehealth. See our GLP-1 Price Index for current rates.

No. Many GLP-1 telehealth programs accept cash-pay patients without insurance, and some also accept insurance for brand-name medications, which can reduce out-of-pocket cost. We cover insurance-friendly options in our dedicated guide.

Brand-name GLP-1s (like Wegovy, Ozempic, Zepbound) are FDA-approved finished products made by pharmaceutical companies. Compounded versions are mixed by state-licensed compounding pharmacies, often at lower cost, and are not FDA-approved. Compounders describe them as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms (semaglutide sodium or acetate) it considers different active ingredients from the approved drug. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding has ended; compounding now proceeds under the ordinary rules: a state-licensed 503A pharmacy compounding for an individual patient on a prescription (for example, a clinically justified personalized dose), or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Separately, the FDA has proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulk drug substances list, citing no identified clinical need; the public comment period, extended to July 30, 2026, has now closed.

Consider five factors: total monthly cost (including medication, consultations, and shipping), medication type offered, clinical support level, cancellation flexibility, and state availability. Our flagship comparison ranks ten programs across all five dimensions.

A legitimate telehealth program should use state-licensed clinicians, physicians or nurse practitioners, who review your medical history before prescribing, consistent with standard prescribing requirements. Look for programs that require lab work, offer ongoing clinical support, and use licensed pharmacies. Our reviews flag any safety concerns for each provider.

Appetite changes are often reported in the early weeks of treatment as the dose is gradually increased, and weight loss typically builds over the following months rather than all at once, in the STEP 1 trial (NEJM 2021, PubMed 33567185), participants on semaglutide 2.4 mg lost an average of 14.9% of body weight over 68 weeks. Timing varies from person to person depending on dose, diet, activity level, and starting weight.

Yes. Many programs are month-to-month with no long-term contract, though terms vary, some charge cancellation fees or require a notice period. We compare cancellation policies in our dedicated guide to help you switch without unexpected charges.